Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
HROW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.86 - $59.23
Previous CloseN/A
Volume51.77K
Average Volume (3M)517.04K
Market Cap
$1.03B
Enterprise Value$1.73B
Total Cash (Recent Filing)$6.64M
Total Debt (Recent Filing)$15.25M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
May 19, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding35,614,720
10 Day Avg. Volume763,041
30 Day Avg. Volume517,045
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.98
Price to Cash Flow (P/CF)85.70
P/FCF Ratio107.50
Enterprise Value/Market Cap1.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.09
Enterprise Value/Ebitda1.97K
Forecast
1Y Price Target
$56.00Price Target Upside100.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePreliminary revenues of $65M-$67M beat our estimate of $58.6M and consensus of $58.4M.
Market StrategyManagement expects 2025 revenue to exceed $280M, which would represent a growth rate over 40%.
Product LaunchHarrow launched VEVYE Access for All, a program that guarantees access to VEVYE eye drops for eligible patients and health plans, potentially accelerating market adoption.
Bears Say
Filing ConcernsA delayed 10-K filing is often a cause for concern; in this case, we take management’s reasoning at face value as the incoming auditor requires additional time.
Regulatory And Market RisksRisks include lower-than-projected market uptake of products, inability to develop and secure regulatory approval of pipeline products, inability to acquire new products, inability to service $216M outstanding debt, and potential dilution risk.
---
Ownership Overview
12.15% Insiders
10.36% Mutual Funds
27.90% Other Institutional Investors
38.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $9.86 and its highest was $59.23 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.03B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is May 19, 2025 which is in 52 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Mar 17, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.082 by $0.078.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is 0.03.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 35,614,720 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of $0.16 in its last earnings report, beating expectations of $0.082. Following the earnings report the stock price went up 15.695%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
---
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.00 (100.93% Upside)
$56.00 (100.93% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 550.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
119.79%
12-Months-Change
Fundamentals
Return on Equity
-50.10%
Trailing 12-Months
Asset Growth
22.76%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
---
HROW Company Deck
---
HROW Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic product launches, particularly with VEVYE and the retina pivot strategy. However, inventory issues with VEVYE and seasonal impacts on revenue were noted as challenges.Read More>---
HROW Stock 12 Month Forecast
Average Price Target
$56.00
▲(100.93% Upside)
Technical Analysis
Prophase Labs
―
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Clearside Biomedical
―
scPharmaceuticals
―
Best Analysts Covering HROW
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+99.41%
reiterated a buy rating 4 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +99.41% per trade.
---